The updated guidelines now include Ga-68 PSMA-11 PET/CT to be considered as an alternative to standard imaging of bone and soft tissue.

PSMA-PET leverages ‘radiotracers’ that bind to prostate cancer cells ·Medical Device Network GlobalData Mon, Jan 6, 2025, 5:05 AM2 min read ...

Moradi, F., et al. (2022) 68 Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment ...

PSMA-PET findings were positive in 80% of patients after radical prostatectomy, 92% after definitive radiotherapy, 85% after radical prostatectomy and salvage radiotherapy, and 84% overall (153 of ...

News Release 6-Jan-2023 PSMA PET/MRI accurately predicts risk of prostate cancer recurrence Peer-Reviewed Publication Society of Nuclear Medicine and Molecular Imaging ...

image: 68Ga-PSMA-11 PET/CT of an 82-year-old male patient with bone pain and PSA levels of 960 ng/ml. The patient was referred to PET/CT without a biopsy.

Session ID: 2025-05-06:e9b9c426fbe6d8f3b77c5549 Player Element ID: V74f312c0_3505_4cdd_ac67_9d5e8221c20e_6367885154112 ...

Using 68 Ga-PSMA PET/CT to monitor treatment response to enzalutamide therapy for metastatic castration-resistant prostate cancer (mCRPC) is more informative than PSA monitoring in predicting ...